Prostate cancer vaccine - Northwest Biotherapeutics
Alternative Names: CaPVax; DC1/HRPC; DCVax-ProstateLatest Information Update: 25 Sep 2021
Price :
$50 *
At a glance
- Originator Northwest Biotherapeutics
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Prostate cancer
Highest Development Phases
- Suspended Prostate cancer
Most Recent Events
- 08 Oct 2014 Phase-III development is still suspended
- 04 Feb 2013 Prostate cancer vaccine - Northwest Biotherapeutics is available for licensing. www.nwbio.com
- 04 Nov 2010 Northwest Biotherapeutics receives a Qualified Therapeutic Discovery Project grant from the US Government for DCVax® development in Cancer